The statistical results of the preclinical validation of the QDEM and xMAP® 3-plex immunoassays detecting AMBP, PRDX2, and PARK7 markers as tools for diagnosis of lung cancer were practically identical. The gene discussed is PARK7; the disease is lung carcinoma.